Articles related to RADIOTHERAPY

“The SunRISe-2 trial was stopped in advance for futility based on week-18 overall response rate assessment and the totality of the efficacy data. However, the CR rates in both arms are compelling.” — Andrea Necchi, MD, ASCO GU Symposium 2026

“At 10 years, BCF was 38.0% for HDR compared with 10.4% for SBRT.” — Udovicich et al., JAMA Network Open, February 2026

PORT is recommended for patients with cSCC having close or positive margins that cannot be corrected with further surgery (secondary to morbidity or adverse cosmetic outcome). In patients with cSCC, PORT is recommended for T3 and T4 tumors—both strong recommendations with moderate to low evidence quality.

Careful management with endocrinology expertise is crucial when considering radioligand therapy for pheochromocytomas and paragangliomas to avoid potentially life-threatening catecholamine crises.

A large-scale randomized controlled trial has identified significant prognostic factors for overall survival (OS) and cancer-specific survival (CSS) in localized prostate cancer, offering new insights into optimizing treatment strategies using surgery and radiotherapy.

In the evolving landscape of radiation oncology, the discussion around supervision models—direct or virtual—presents a pivotal moment for the field. This debate not only impacts patient access and safety but also stresses upon the profession’s adaptability in integrating technology while preserving core clinical standards.